Advancements in Biopharma Spur Innovation Christian Cobaugh, chief scientific officer and founder of Vernal Biosciences, offered PharmaTech editor Susan Haigney comments about where he believes mRNA and LNP advancements fit into the biopharm innovation landscape. Source: Pharmaceutical Technology, June 2025,…
Well-Defined mRNA Platform Processes & Collaboration Advanced a Novel Gene Therapy in Jeopardy Learn how Vernal Bio changed the course of a stalled cancer gene therapy program, pairing proven mRNA platform methods with scientific flexibility and hands-on collaboration. Innovator’s Challenges…
Awakening the Giant: The Next Frontier in mRNA Therapeutics We’ve seen what mRNA can do in vaccines—but that was only the beginning. In a new article published in American Pharmaceutical Review , Vernal’s CSO Christian Cobaugh, Ph.D., outlines how mRNA…
Messenger RNA has redefined what rapid looks like in drug development. Yet the very flexibility that makes mRNA attractive also makes it unforgiving—minute variations in purity, structure, or LNP encapsulation can eliminate potency or introduce safety risks. It’s never too soon to…
The remarkable success of messenger RNA-based vaccines during the COVID-19 pandemic has sparked widespread interest and enthusiasm around mRNA technology. But vaccines are just the beginning. Researchers and biotech innovators worldwide are rapidly uncovering the broader potential of mRNA to…
The Evolving Needs of Therapeutic mRNA Developers Insights on the next wave of challenges mRNA innovators face as an increasing number of therapeutics move through the pipeline. Read Article Behind the Headlines Panel Discussion Christian Cobaugh, Ph.D., Vernal Biosciences founder…
How Vernal Helped Akagera Boost Vaccine Efficacy, Cut Costs, and Speed Development Pioneering mRNA Therapies for Infectious Diseases in Cost-Sensitive Regions Founded in 2019, Akagera Medicines is advancing novel liposomal formulations of antibacterial drugs to enhance drug delivery and uptake…
Given the strides medical researchers and therapeutic developers were making, the possibility of commercializing mRNA therapeutics began looking bright about ten to fifteen years ago. However, one of the most pressing issues restricting researchers’ efforts was the lack of a…
In the fast-paced world of biopharmaceuticals, choosing the right contract development and manufacturing organization (CDMO) is crucial to the success of your drug development program. At Vernal Biosciences, we pride ourselves on being a US-based CDMO that produces all products domestically. Here…
If you are not on our mailing list, email us at [email protected]! You can click “contact us” in the upper right hand corner of this webpage to inquire about our Cas9 Demo batch, and HERE to watch the video of…
Experience the incredible insights Vernal has to offer regarding its cutting-edge capping technology and the exceptional quality of our mRNA. We will be showcasing this groundbreaking information through three posters at the International mRNA Health Conference in Berlin. You can…
CRISPR-Cas9 RNA-DNA complex. Structure of Cas9 endonuclease (yellow-orange) complexed with a guide RNA (blue), a target DNA (pink) and a non-target DNA (green). The revolutionary CRISPR-Cas gene editing technology has unlocked unprecedented possibilities in genome engineering, gene therapy, and cell…